Study study type PathologyT1T0Patientssample sizesROB Results

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
IMpower-131 (ACnP), 2020
  NCT02367794
RCTsquamous - mNSCLC - L1 - all populationatezolizumab plus carboplatine plus nab-paclitaxel(ACnP)carboplatine plus nab-paclitaxel (CnP)chemotherapy-naive participants with Stage IV squamous NSCLC343 / 340some concern
conclusif
  • inconclusive 12 % decrease in deaths (OS),deaths (OS) (PE)
  • demonstrated 29 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE)
  • statistically significant 1.1-fold increase in DOR,DOR
versus placebo plus SoC
ipilimumab plus SoC
CA184-104, 2017
 
NCT01285609
RCTsquamous - mNSCLC - L1 - all populationipilimumab plus paclitaxel and carboplatinplacebo plus paclitaxel and carboplatinpatients treated with first-line in advanced stage IV squamous NSCLC479 / 477high
inconclusive
  • inconclusive 9 % decrease in deaths (OS) (PE)
  • statistically significant 27 % decrease in objective responses (ORR)
pembrolizumab plus SoC
KEYNOTE-407, 2018
  NCT02775435
RCTsquamous - mNSCLC - L1 - all populationpembrolizumab plus platine and (nab)paclitaxelplacebo plus platine and (nab)paclitaxelpatients with confirmed stage IV squamous NSCLC who had received no previous systemic therapy for metastatic disease278 / 281low
conclusif
  • demonstrated 36 % decrease in deaths (OS) (PE)
  • demonstrated 44 % decrease in progression or deaths (PFS) (PE)